WorksheetsRAPID India study CSM quiz June-25
Total questions: 10
Worksheet time: 4mins
The consensus report of RAPID India was published in ______
Indian Journal of Rheumatology
Indian journal of Orthopedics
Immunology '2025
Indian journal of medical sciences
The steering committee of 6 prepared ____ consensus statements and followed Delhpi technique to finally get the insights of RAPID India consensus.
6
12
22
26
______ is recommended as upfront choice or first line drug in patients with aggressive early RA and in established RA with poor prognostic factors after failure of conventional treatment
Methotrexate
Adalimumab
Tocilizumab
Tofacitinib
Treatment for patients with Inadequate response with MTX at 3 months and poor prognostic factors is
To Add ADA
To increase MTX dose
Shift to another Cs DMARDS
None of these
Choose the right special population patients where Adalimumab can be preferred in the treatment of axSPA
Pregnancy upto 2nd trimester
Lactation
CKD
Osteroporosis and metabolic diseases
Adalimumab is an upfront choice in active axSpA with extra-musculoskeletal manifestations like uveitis, Psoriasis & IBD
True
False
Choose the right statements in relevance to the treatment with Adalimumab in the treatment of axSPA
If the patients show no response after 3 months of Initiation of Adalimumab switch to another bDMARD or Jaki
In the patients with Axial SPA with NSAIDs therapy atleast for 4 weeks must be intiated on Tofacitinib
If the patient showed improvement by the end of 3 months, continue ADA therapy every 2 weeks
Adalimumab is an upfront choice in active axSpA with extra-musculoskeletal manifestations like uveitis, Psoriasis & IBD
The panel recommends the use of ___________ in patients who experience injection site reactions with conventional Adalimumab leading to drug discontinuation.
citrate-free formulation
low volume
29-gauge needle
All of these
What is the recommended action if a patient with PsA shows improvement at 3 months?
Continue ADA therapy every 2 week
Switch to another bDMARD
Discontinue ADA
Reduce the dose of ADA
What is the recommended action if a patient with PsA has a flare after tapering down the dose?
Continue ADA therapy every 2 week
Switch to another bDMARD
Discontinue ADA
Reduce the dose of ADA
